Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 389

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

Open access
Moreland, Larry W., O'Dell, James R., Paulus, Harold E., Curtis, Jeffrey R., Bathon, Joan M., St.Clair, E. William, Bridges, S. Louis, Zhang, Jie, McVie, Theresa, Howard, George, van der Heijde, Désirée, Cofield, Stacey S., TEAR Investigators·2012·Arthritis & Rheumatism

Abstract

Objective: To assess whether it is better to intensively treat all patients with early rheumatoid arthritis (RA) using combinations of drugs or to reserve this approach for patients who do not have an appropriate response (as determined by a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [DAS28‐ESR] of ≥3.2 at week 24) to methotrexate (MTX) monotherapy, and to assess whether combination therapy with MTX plus etanercept is superior to the combination of MTX plus sulfasalazine plus hydroxychloroquine. Methods: The Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) study is a 2‐year, randomized, double‐blind trial. A 2 × 2 factorial design was used to randomly assign subjects to 1 of 4 treatment arms: immediate treatment with MTX plus etanercept, immediate oral triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or step‐up from MTX monotherapy to one of the combination therapies (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine) at week 24 if the DAS28‐ESR was ≥3.2. All treatment arms included matching placebos. The primary outcome was an observed‐group analysis of DAS28‐ESR values from week 48 to week 102. Results: At week 24 (beginning of the step‐up period), subjects in the 2 immediate‐treatment groups demonstrated a greater reduction in the DAS28‐ESR compared with those in the 2 step‐up groups (3.6 versus 4.2; P < 0.0001); no differences between the combination‐therapy regimens were observed. Between week 48 and week 102, subjects randomized to the step‐up arms had a DAS28‐ESR clinical response that was not different from that of subjects who initially received combination therapy, regardless of the treatment arm. There was no significant difference in the DAS28‐ESR between subjects randomized to oral triple therapy and those randomized to receive MTX plus etanercept. By week 102, there was a statistically significant difference in the change in radiographic measurements from baseline between the group receiving MTX plus etanercept and the group receiving oral triple therapy (0.64 versus 1.69; P = 0.047). Conclusion: There were no differences in the mean DAS28‐ESR during weeks 48–102 between subjects randomized to receive MTX plus etanercept and those randomized to triple therapy, regardless of whether they received immediate combination treatment or step‐up from MTX monotherapy. At 102 weeks, immediate combination treatment with either strategy was more effective than MTX monotherapy prior to the initiation of step‐up therapy. Initial use of MTX monotherapy with the addition of sulfasalazine plus hydroxychloroquine (or etanercept, if necessary, after 6 months) is a reasonable therapeutic strategy for patients with early RA. Treatment with the combination of MTX plus etanercept resulted in a statistically significant radiographic benefit compared with oral triple therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34498

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 389

Metadata

Authors
Moreland, L. W., O'Dell, J. R., Paulus, H. E., Curtis, J. R., Bathon, J. M., St.Clair, E. W., Bridges, S. L., Zhang, J., McVie, T., Howard, G., van der Heijde, D., Cofield, S. S., & TEAR Investigators
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-08-27
Volume
64
Issue
9
Pages
2824-2835
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2028764755
Cited by
389
References
3
FWCI
34.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. https://app.cochat.ai/papers/10.1002/art.34498
The paper
Moreland, L. W., O'Dell, J. R., Paulus, H. E., Curtis, J. R., Bathon, J. M., St.Clair, E. W., Bridges, S. L., Zhang, J., McVie, T., Howard, G., van der Heijde, D., Cofield, S. S., & TEAR Investigators. (2012). A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.34498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.